Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1, 4]diazepin-11-one-based potent and selective Chk-1 inhibitors

Journal of Medicinal Chemistry

Volumn 50, Issue 17, 2007, Pages 4162-4176

  Wang, Le ^a   Sullivan, Gerard M ^a   Hexamer, Laura A ^a   Hasvold, Lisa A ^a   Thalji, Reema ^a,b,c   Przytulinska, Magdalena ^a   Tao, Zhi Fu ^a   Li, Gaoquan ^a   Chen, Zehan ^a   Xiao, Zhan ^a   Gu, Wen Zhen ^a   Xue, John ^a   Bui, Mai Ha ^a   Merta, Philip ^a   Kovar, Peter ^a   Bouska, Jennifer J ^a   Zhang, Haiying ^a   Park, Chang ^a   Stewart, Kent D ^a   Sham, Hing L ^a   Sowin, Thomas J ^a   Rosenberg, Saul H ^a   Lin, Nan Horng ^a   more..

^a ABBOTT LABORATORIES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 (3 METHOXY 4 NITROPHENYL) 11 OXO 10,11 DIHYDRO 5H DIBENZO[B,E][1,4] DIAZEPIN 7 YL] 2 METHYL N (4 MORPHOLIN 4 YLPHENYL)PROPANAMIDE; 2 [3 (3 METHOXY 4 NITROPHENYL) 11 OXO 10,11 DIHYDRO 5H DIBENZO[B,E][1,4] DIAZEPIN 7 YL] N,N DIMETHYLACETAMIDE; 2 [3 (3 METHOXY 4 NITROPHENYL) 11 OXO 10,11 DIHYDRO 5H DIBENZO[B,E][1,4] DIAZEPIN 8 YL] 2 METHYL N (4 MORPHOLIN 4 YLPHENYL)PROPANAMIDE; 2 [3 (3 METHOXY 4 NITROPHENYL) 11 OXO 10,11 DIHYDRO 5H DIBENZO[B,E][1,4] DIAZEPIN 8 YL] N,N DIMETHYLACETAMIDE; 3 [3 (3 METHOXY 4 NITROPHENYL) 11 OXO 10,11 DIHYDRO 5H DIBENZO[B,E][1,4] DIAZEPIN 8 YL] N,N DIMETHYLPROPANAMIDE; AMIDE; CAMPTOTHECIN; CHECKPOINT KINASE 1; CISPLATIN; DIAZEPINE DERIVATIVE; DOXORUBICIN; LYSINE; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; AZEPINES; BENZODIAZEPINONES; BIOLOGICAL AVAILABILITY; CAMPTOTHECIN; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DOXORUBICIN; DRUG DESIGN; DRUG SYNERGISM; HUMANS; MICE; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34548118639     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070105d     Document Type: Article

References (35)

1. (a) Liu, Q.; Guntuku, S.; Cui, X.; Matsuoka, S.; Cortez, D.; Tamai, K.; Carattini-Rivera, S.; DeMayo, F.; Bradley, A.; Donehower, L. A.; Elledge, S. J. Chk1 is an essential kinase that is regulated by ATR and required for the G2/M DNA damage checkpoint. Genes Dev. 2000, 14, 1448-1459.
2. (b) Sanchez, Y.; Wong, C.; Thoma, R. S.; Richman, R.; Wu, Z.; Piwinca-Worms, H.; Elledge, S. J. Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25. Science 1997, 277, 1497-1501.
3. Abraham, R. T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 2001, 15, 2177-2196.
4. 2 arrests through Cdc25A degradation in response to DNA-damaging agents. J. Biol. Chem. 2003, 278, 21767-21773.
5. 2/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J. 2002, 21, 5911-5920.
6. (a) Russell, K. J.; Wiens, L. W.; Demers, G. W.; Galloway, D. A.; Plon, S. E.; Groudine, M. Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells. Cancer Res. 1995, 55, 1639-1642.
7. (b) Powell, S, N.; DeFrank, J. S.; Connell, P.; Eogan, M.; Preffer, F.; Dombkowski, D.; Tang, W.; Friend, S. Differential sensitivity of p53-(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res. 1995, 55, 1643-1648.
8. (c) Bunch, R. T.; Eastman, A. 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. Cell Growth Differ. 1997, 8, 779-88.
9. 2 cell cycle checkpoints. Cancer Res. 2003, 63, 31-35.
10. (a) Ozbun, M. A.; Butel, J. S. Tumor suppressor p53 mutations and breast cancer: A critical analysis. Adv. Cancer Res. 1995, 66, 71-141.
11. (b) Bartek, J.; Lukas, J. Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr. Opin. Cell Biol. 2001, 13, 738-47.
12. (c) Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57-70.
13. (a) Powell, S. N.; DeFrank, J. S.; Connell, P.; Eogan, M.; Preffer, F.; Domkowski, D.; Tang, W.; Friend, S. Differential sensitivity of p53(-•) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res. 1995, 55, 1643-1648.
14. (b) Kawabe, T. G2 checkpoint abrogators as anticancer drugs. Mol. Cancer Ther. 2004, 3, 513-519.
15. (a) Wang, H.; Wang, X.; Zhou, X.-Y.; Chen, D. J.; Li, G. C.; Iliakis, G.; Wang, Y. Ku Affects Ataxia and Rad 3-releated/Chk1-dependent S phase checkpoint response after camptothecin treatment. Cancer Res. 2002, 62, 2483-2487.
16. (b) Chen, Z.; Xiao, Z.; Chen, J.; Ng, S. C.; Sowin, T.; Sham, H. L.; Rosenberg, S. H.; Fesik, S.; Zhang, H. Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol. Cancer Ther. 2003, 2, 543-548.
17. (a) Li, Q.; Zhu, G.-D. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. Curr. Top. Med. Chem. 2002, 2, 939-971.
18. 2 checkpoint abrogators. Curr. Med. Chem. 2003, 3, 35-46.
19. Jackson, J. R.; Gilmartin, A.; Imburgia, C.; Winkler, J. D.; Marshall, L. A.; Roshak, A. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res. 2000, 60, 566-572.
20. Roberge, M.; Berlinck, R. G. S.; Xu, L.; Anderson, H. J.; Lim, L. Y.; Curman, D.; Stringer, C. M.; Friend, S. H.; Davies, P.; Inez, V.; Haggarty, S. J.; Kelly, M. T.; Britton, R.; Piers, E.; Andersen, R. J. High-throughput assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide. Cancer Res. 1998, 58, 5701-5706.
21. 2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J. Biol. Chem. 2001, 276, 17914-17919.
22. (a) Graves, P. R.; Yu, L.; Schwarz, J. K.; Gales, J.; Sausville, E. A.; O'Connor, P. M.; Piwinca-Worms, H. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem. 2000, 275, 5600-5605.
23. (b) Busby, E. C.; Leistritz, D. F.; Abraham, R. T.; Karnitz, L. M.; Sarkaria, J. N. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res. 2000, 60, 2108-2112.
24. (a) Ninkvoic, S.; Bennett, M. J.; Rui, E. Y.; Wang, F.; Benedict, S. P.; Teng, M. WO 2004/063198, 2004.
25. (b) Anderes, K. L.; Blasina, A.; Castillo, R.; Chen, E.; Gregory, M.; Herrera, J.; Kornmann, J.; Kraynov, E.; Stempniak, M. Small molecule Chk1 inhibitor potentiates antitumor activity of chemotherapeutic agents in vivo. AACR annual meeting, April 16-20, Anaheim, CA, 2005, poster No. 4417.
26. Gesner, T. G.; Barsanti, P. A.; Harrison, S. D.; Ni, Z.-J.; Brammeier, N. M.; Zhou, Y.; Le, V. P. Combination therapy with Chk1 inhibitors. U.S. 2005/0256157, 2005.
27. Boyle, R. G.; Imogai, H. J.; Cherry, M.; Humphries, A. J.; Navarro, E. F.; Owen, D. R.; Dales, N. A.; Lamarche, M.; Cullis, C.; Gould, A. E. WO 2005/028474, 2005.
28. (a) Wang, G. T.; Li, G.; Mantei, R. A.; Chen, Z.; Kovar, P.; Gu, W.; Xiao, Z.; Zhang, H.; Sham, H. L.; Sowin, T.; Rosenberg, S. H.; Lin, N.-H. 1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyano-pyrazi-2-yl)ureas as potent and selective inhibitors of Chk1 kinase: Synthesis, preliminary SAR, and biological activities. J. Med. Chem. 2005, 48, 3118-3121.
29. (b) Boyle, R. G.; Imogai, H. J.; Cherry, M. Diaryl urea compounds and derivatives as Chk1 inhibitors for the treatment of cancer. WO 03/101444, 2003.
30. (c) Keegan, K.; Kesicki, E. A.; Gaudino, J. J.; Cook, A. W.; Cowen, S. D.; Gurgess, L. E. Aryl and heteroaryl urea Chk1 inhibitors for use as radiosensitizers and chemosensitizers. WO 02/070494, 2002.
31. Chen, P.; Luo, C.; Deng, Y.; Ryan, K.; Register, J.; Margosiak, S.; Tempczyk-Russell, A.; Nguyen, B.; Myers, P.; Lundgren, K.; Kan, C.-C.; O'Connor, P. M. The 1.7 Å crystal structure of human cell cycle checkpoint kinase Chk1: Implications for Chk1 regulation. Cell 2000, 100, 681-692.
32. Giani, R. P.; Borsa, M.; Parini, E.; and Tonon, G. C. A new facile synthesis of 11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepines Synthesis 1985, 5, 550-552.
33. Ishiyama, T.; Ishida, K.; Miyaura, N. Synthesis of pinacol arylboronates via cross-coupling reaction of bis(pinacolato)diboron with chloroarenes catalyzed by palladium(0)-tricyclohexylphosphine complexes. Tetrahedron 2001, 57, 9813-9816.
34. Li, G.; Hasvold, L. A.; Tao, Z.-F.; Wang, G. T.; Gwaltney, S. L., II; Patel, J.; Kovar, P.; Credo, R. B.; Chen, Z.; Zhang, H.; Park, C.; Sham, H. L.; Sowin, T.; Rosenberg, S. H.; Lin, N.-H. Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 2293-2298.
35. Lin, N.-H.; Xia, P.; Kovar, P.; Park, C.; Chen, Z.; Zhang, H.; Rosenberg, S. H.; Sham, H. L. Synthesis and biological evaluation of 3-ethylidene-1,3- dihydro-indol-2-ones as novel checkpoint 1 inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 421-426.